Novartis licenses radiopharma asset from Chinese biotech for $50M upfront
诺华以5000万美元预付款从一家manbetx3.0 生物科技公司获得一项放射性药物资产的许可

Novartis is paying $50 million upfront to license a peptide-based radiopharmaceutical asset from China-headquartered Zonsen PepLib Biotech.
诺华以预付款5000万美元从总部位于manbetx3.0 的Zonsen PepLib Biotech许可获得一项peptide-based radiopharmaceutical资产。